On July 3, National Healthcare Security Administration Medical Price and bidding Purchasing guidance Center issued a document on entrustment.National Organization purchase Program for centralized carrying capacity of Coronary Stents (draft for soliciting opinions)The purchase of high-value consumables similar to the drug "4-7" at the national level has been put on the agenda for the first time.
According to the analysis of industry insiders, the national mining of high-value consumables will start in September as soon as possible.
Photo source: insignt database, Futu Securities arrangement
At that time, the coronary stent field will face the biggest "impact event" in history. What does this mean for hospitals, manufacturers and patients? Who will take advantage of the counterattack and who will lose the market?
At present, the domestic replacement rate of coronary stents (red is the target of this round) has reached 70%.The technical barrier of coronary stent is relatively low, and the industry scale is large. At present, the proportion of the third generation of coronary stents is as high as 99%, and the competition pattern is stable, and the concentration of the market is also steadily increasing.
According to the picture below, we can see that there are four major domestic suppliers: Lepu Medical, minimally invasive Medical, Geway Medical and Saino Medical. Minimally invasive has always maintained the leading position of coronary stents, but there is not a big gap with the second and third places. But it's worth noting thatThe products of Saino Medical are made of stainless steel and do not meet the requirements.Other companies have qualified main products and are qualified to participate in collection.
Data sources: Sainuo Medical, Huajing Intelligence Network, Futu Securities
In addition, in terms of price, in the face of the national market, we can refer to the price of consumable materials in Beijing: at present, the unit price of domestic coronary stents is about 7000 yuan, the import is more than 10000 yuan, and the proportion of medical insurance payment is not less than 70%. After the price reduction, the proportion of health insurance payments is expected to further increase, if the reduction is more than 50%, ideally patients only need to pay less than 1000 yuan themselves.
Pay attention to the target
Hong Kong stock: minimally invasive medical treatment
A shares: Lepu Medical, Blue Sail Medical
Edit / elisa